TEAD Inhibitors Sensitize KRAS^G12C Inhibitors via Dual Cell Cycle Arrest in KRAS^G12C-Mutant NSCLC

KRAS^G12C is one of the most common mutations detected in non-small cell lung cancer (NSCLC) patients, and it is a marker of poor prognosis. The first FDA-approved KRAS^G12C inhibitors, sotorasib and adagrasib, have been an enormous breakthrough for patients with KRAS<sup>G12C</s...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Salvina Laura Tammaccaro, Philippe Prigent, Jean-Christophe Le Bail, Odette Dos-Santos, Laurent Dassencourt, Myriam Eskandar, Armelle Buzy, Olivier Venier, Jean-Claude Guillemot, Yaligara Veeranagouda, Michel Didier, Emmanuel Spanakis, Tokuwa Kanno, Matteo Cesaroni, Stephane Mathieu, Luc Canard, Alhassan Casse, Fanny Windenberger, Loreley Calvet, Laurence Noblet, Sukhvinder Sidhu, Laurent Debussche, Jurgen Moll, Iris Valtingojer
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	MDPI AG 2023-04-01
Saila:	Pharmaceuticals
Gaiak:	YAP1-TEAD resistance KRAS<sup>G12C</sup> NSCLC cell cycle arrest
Sarrera elektronikoa:	https://www.mdpi.com/1424-8247/16/4/553
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!